Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Opportunities to Optimize Cancer Policies Panel Discussion

Deborah Collyar: What's In It for Patients?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement




Mar
05
Today In Oncology
Black Patients With AML Face Younger Onset and Significantly Worse Survival Outcomes
CD123-Targeting ADC Shows Activity in AML and BPDCN
Combined Tests Could Avoid Unnecessary Cystectomy, Study Finds
Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence
Research Suggests AI Pathology Models May Take Unreliable Shortcuts to Identify Cancer Biomarkers
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo